Definitive Healthcare Corp. (DH) Guidance & Earnings Results

On 2026-08-10 Definitive Healthcare Corp. reaffirmed guidance: "Q3 2026 revenue $54-55M; FY2026 revenue…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DHDefinitive Healthcare Corp.Follow DH — free

Health Information Services · Healthcare

—

Price chart with a free account

Market cap: 115.3M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
10 Aug 26	Reaffirmed	Q3 2026 revenue $54-55M; FY2026 revenue $220-222M · full year
7 May 26	Reaffirmed	Q2 2026 revenue $55-56M; FY2026 revenue $220-226M; Q2 adjusted EBITDA $13.5-14.5M; FY adjusted EBITDA $55-59M; Q2 adjusted net income $5-6M; FY adjusted net income $23-27M; Q2 adjusted EPS $0.03-0.04; FY adjusted EPS $0.16-0.19 · full year
26 Feb 26	Lowered	FY2026 revenue $220-226M vs FY2025 $241.5M; Q1 2026 revenue $54-56M; FY2026 adjusted EBITDA $53-58M (24-26% margin); FY2026 adjusted net income $21-26M; FY2026 adjusted EPS $0.14-0.17. · full year
6 Nov 25	Raised	FY25 revenue raised to $239-240M from $237-240M; Q4 revenue $59-60M; Q4 adjusted EBITDA $16-17M; FY25 adjusted EBITDA $68-69M; Q4 adjusted net income $8-9M; FY25 adjusted net income $34-35M; Q4 adjusted EPS $0.05-0.06; FY25 adjusted EPS $0.23-0.24 · full year
7 Aug 25	Raised	FY2025 revenue raised to $237-240M from $234-240M; FY2025 adjusted EBITDA raised to $64-67M; Q3 2025 revenue $59-60M, adjusted EBITDA $15.5-16.5M · full year

Definitive Healthcare Corp. — questions

What guidance did Definitive Healthcare Corp. give?: On 2026-08-10: "Q3 2026 revenue $54-55M; FY2026 revenue $220-222M"
When does Definitive Healthcare Corp. report earnings?: Definitive Healthcare Corp.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Definitive Healthcare Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.